Andrew Levin

Andrew Levin is a Partner and Managing Director at RA Capital Management, where he focuses on building and investing in early-stage life sciences companies. An MD from Harvard and a PhD from MIT, he leverages his deep scientific and medical background to spearhead drug discovery and development efforts.

Andrew is a vocal supporter of free speech within the biotech community and shows a strong interest in the complexities of healthcare policy. His public posts reveal a critical perspective on industry practices, particularly concerning the role of Pharmacy Benefit Managers (PBMs) in the healthcare system.

He co-founded several biotech companies, including Carnot Pharm and Climb Bio (formerly Eliem Therapeutics), where he also served as CEO.